AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35045226 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster
Number of subjects: 0
Study 35045226 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA‐1273 booster
Number of subjects: 0
Study 35045226 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 booster
Number of subjects: 0
Study 35045226 — intervention group
Group type: COMPARATOR
Intervention: No booster
Number of subjects: 0
Study 34625057 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 69
Study 34625057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 32762109 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated brachial-ankle PWV (baPWV) using Microlife WatchBP Office Vascular
Number of subjects: 97
Study 32762109 — intervention group
Group type: COMPARATOR
Intervention: Reference carotid-femoral PWV (cfPWV) using Complior device
Number of subjects: 97
Study 32762109 — intervention group
Group type: COMPARATOR
Intervention: Comparison of baPWV and cfPWV
Number of subjects: 97
Study 32762109 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with age
Number of subjects: 97
Study 32762109 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with systolic blood pressure
Number of subjects: 97
Study 32762109 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with carotid intima-media thickness
Number of subjects: 97
Study 32762109 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with carotid distensibility coefficient
Number of subjects: 97
Study 32762109 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement in identifying subjects at top quartile
Number of subjects: 97
Study 32762109 — intervention group
Group type: COMPARATOR
Intervention: Areas under the receiver operating characteristic curves for carotid plaques
Number of subjects: 97
Study 36228662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intersectoral discharge program (TIDP)
Number of subjects: 110
Study 36228662 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitative care
Number of subjects: 110
Study 34251106 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer posterior reconstruction of the vesicourethral anastomosis (VUA)
Number of subjects: 67
Study 34251106 — intervention group
Group type: COMPARATOR
Intervention: Standard technique of the vesicourethral anastomosis (VUA)
Number of subjects: 67
Study 33512795 — intervention group
Group type: EXPERIMENTAL
Intervention: DCL-101 (3L in cohort 1; 4L in cohort 2)
Number of subjects: 45
Study 33512795 — intervention group
Group type: COMPARATOR
Intervention: 4L PEG-ELS
Number of subjects: 45
Study 33512795 — intervention group
Group type: EXPERIMENTAL
Intervention: DCL-101 and 4L PEG-ELS
Number of subjects: 45
Study 36414367 — intervention group
Group type: EXPERIMENTAL
Intervention: Position change and back massage (PCBM)
Number of subjects: 185
Study 36414367 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ambulation (EA)
Number of subjects: 185
Study 35013615 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab with enzalutamide
Number of subjects: 759
Study 33482741 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric assessment (GA) with intervention, using an instant report to guide physician's choice of intervention.
Number of subjects: 1000
Study 33482741 — intervention group
Group type: COMPARATOR
Intervention: Standard practice without GA intervention.
Number of subjects: 1000
Study 616852759 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency fulguration combined with 5% imiquimod cream
Number of subjects: 112
Study 616852759 — intervention group
Group type: COMPARATOR
Intervention: High-frequency fulguration combined with intramuscular injection of Bacillus Calmette-Guerin polysaccharide nucleic acid
Number of subjects: 112
Study 35771569 — intervention group
Group type: EXPERIMENTAL
Intervention: BG00011 56 mg once-weekly subcutaneous
Number of subjects: 106
Study 35771569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 35771569 — intervention group
Group type: EXPERIMENTAL
Intervention: BG00011
Number of subjects: 106
Study 34584280 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 70
Study 34584280 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 70
Study 33576291 — intervention group
Group type: EXPERIMENTAL
Intervention: myPlan app
Number of subjects: 346
Study 33576291 — intervention group
Group type: COMPARATOR
Intervention: Usual web‐based safety planning resources
Number of subjects: 346
Study 33515990 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F (18.8% fat, 47.6% lactose)
Number of subjects: 40
Study 33515990 — intervention group
Group type: EXPERIMENTAL
Intervention: 22F (22.3% fat, 42.8% lactose)
Number of subjects: 40
Study 33515990 — intervention group
Group type: EXPERIMENTAL
Intervention: 26F (26.0% fat, 38.6% lactose)
Number of subjects: 40
Study 33515990 — intervention group
Group type: EXPERIMENTAL
Intervention: 30F (30.1% fat, 33.8% lactose)
Number of subjects: 40
Study 33515990 — intervention group
Group type: COMPARATOR
Intervention: Glucose Tolerance Test (GTT) for 18F
Number of subjects: 40
Study 33515990 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose Tolerance Test (GTT) for 22F
Number of subjects: 40
Study 33515990 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose Tolerance Test (GTT) for 26F
Number of subjects: 40
Study 32179138 — intervention group
Group type: EXPERIMENTAL
Intervention: Camino Verde intervention using community health workers (brigadistas) for dengue prevention
Number of subjects: 150
Study 32179138 — intervention group
Group type: COMPARATOR
Intervention: Control communities
Number of subjects: 150
Study 32179138 — intervention group
Group type: EXPERIMENTAL
Intervention: Camino Verde intervention
Number of subjects: 150
Study 34236302 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch (Laboratorios Gebro Pharma, SA)
Number of subjects: 5
Study 34236302 — intervention group
Group type: COMPARATOR
Intervention: Versatis 5% lidocaine patch (Grünenthal)
Number of subjects: 5
Study 34614432 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver resection (LR)
Number of subjects: 627
Study 34614432 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 627
Study 34614432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 627
Study 34614432 — intervention group
Group type: COMPARATOR
Intervention: Control group (type IV PVTT)
Number of subjects: 627
Study 33461319 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial suspension of P. extremorientalis strain ZJH1 (10 μL of 10^8 CFU/ml) inoculated into healthy P. ternata plants.
Number of subjects: 20
Study 33461319 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control) inoculated into healthy P. ternata plants.
Number of subjects: 20
Study 34820710 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention telephone health coaching calls
Number of subjects: 14
Study 34659105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration measured at baseline and after 12 months
Number of subjects: 786
Study 34659105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair cortisol concentration measured at 12 months
Number of subjects: 786
Study 34659105 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 12‐month increase in log hair cortisol concentration
Number of subjects: 786
Study 32522790 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening interval of 2 years for type 1 DM
Number of subjects: 25745
Study 32522790 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening interval of 3 years for type 2 DM
Number of subjects: 25745
Study 32522790 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening interval of 4 years for low-risk patients with type 2 DM
Number of subjects: 25745
Study 32522790 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year cumulative incidence of referable DR for type 1 DM
Number of subjects: 25745
Study 32522790 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-year cumulative incidence of referable DR for type 2 DM
Number of subjects: 25745
Study 33080991 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 263
Study 33080991 — intervention group
Group type: COMPARATOR
Intervention: Control group (laparoscopic cholecystectomy without conversion)
Number of subjects: 263
Study 34936531 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program (LMP) for 6 months
Number of subjects: 194
Study 34936531 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 6 months
Number of subjects: 194
Study 32892756 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised lunch providing 1.5 g/kg body mass of carbohydrate
Number of subjects: 108
Study 32383574 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electric stimulation in posturally corrected position (Group 1)
Number of subjects: 44
Study 32383574 — intervention group
Group type: COMPARATOR
Intervention: Motor program activating therapy (Group 2)
Number of subjects: 44
Study 35388922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed models of craniosynostosis
Number of subjects: 85
Study 35388922 — intervention group
Group type: COMPARATOR
Intervention: 2D reconstructions of craniosynostosis
Number of subjects: 85
Study 33616765 — intervention group
Group type: COMPARATOR
Intervention: Control group (G1) received only conventional therapy with occlusal splint (OS)
Number of subjects: 70
Study 33616765 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo group (G2) received treatment with OS and LED therapy (device turned off)
Number of subjects: 70
Study 33616765 — intervention group
Group type: EXPERIMENTAL
Intervention: LED therapy (G3) once a week
Number of subjects: 70
Study 33616765 — intervention group
Group type: EXPERIMENTAL
Intervention: LED therapy (G4) twice a week
Number of subjects: 70
Study 33616765 — intervention group
Group type: EXPERIMENTAL
Intervention: OS associated with LED therapy (G5) once a week
Number of subjects: 70
Study 33616765 — intervention group
Group type: EXPERIMENTAL
Intervention: OS therapy plus infrared LED (G6) two sessions per week
Number of subjects: 70
Study 32761980 — intervention group
Group type: COMPARATOR
Intervention: Zembrin® (25 mg)
Number of subjects: 20
Study 33544195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined alcohol (target BrAC 0.08%) and cannabis (12.5% THC)
Number of subjects: 0
Study 33544195 — intervention group
Group type: COMPARATOR
Intervention: Alcohol (target BrAC 0.08%)
Number of subjects: 0
Study 33544195 — intervention group
Group type: COMPARATOR
Intervention: Placebo alcohol and active cannabis
Number of subjects: 0
Study 33544195 — intervention group
Group type: COMPARATOR
Intervention: Placebo alcohol and placebo cannabis
Number of subjects: 0
Study 33544195 — intervention group
Group type: COMPARATOR
Intervention: Active cannabis (12.5% THC)
Number of subjects: 0
Study 33166627 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoconstituents (specifically cannabidiol and tetrahydrocannabinol)
Number of subjects: 50000000
Study 33166627 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytoconstituents (cannabidiol and tetrahydrocannabinol)
Number of subjects: 50000000
Study 36361052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 90 min once a week for 4 weeks
Number of subjects: 60
Study 36361052 — intervention group
Group type: COMPARATOR
Intervention: Control (non-CBT-I)
Number of subjects: 60
Study 36361052 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 60
Study 35927776 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary stenting combined with iodine‐125 seed strand implantation
Number of subjects: 60
Study 35927776 — intervention group
Group type: COMPARATOR
Intervention: Biliary stent implantation alone (Control group)
Number of subjects: 60
Study 33421203 — intervention group
Group type: EXPERIMENTAL
Intervention: 100Asp
Number of subjects: 24
Study 33421203 — intervention group
Group type: EXPERIMENTAL
Intervention: 125Asp
Number of subjects: 24
Study 33421203 — intervention group
Group type: EXPERIMENTAL
Intervention: 125Reg
Number of subjects: 24
Study 33421203 — intervention group
Group type: EXPERIMENTAL
Intervention: 100:25Asp
Number of subjects: 24
Study 32844517 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD group without language disorder
Number of subjects: 3
Study 32844517 — intervention group
Group type: COMPARATOR
Intervention: Control group (typically developing)
Number of subjects: 3
Study 32844517 — intervention group
Group type: EXPERIMENTAL
Intervention: DLD group
Number of subjects: 3
Study 35912159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided sciatic nerve block anesthesia (UG-SNBA) under 3D reconstruction algorithm
Number of subjects: 68
Study 35912159 — intervention group
Group type: COMPARATOR
Intervention: Sciatic nerve block anesthesia (SNBA)
Number of subjects: 68
Study 35912159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided sciatic nerve block anesthesia (UG-SNBA)
Number of subjects: 68
Study 33515092 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose with 25 g pea protein (Test 1)
Number of subjects: 31
Study 33515092 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose with 50 g pea protein (Test 2)
Number of subjects: 31
Study 33515092 — intervention group
Group type: COMPARATOR
Intervention: 50 g glucose (Control)
Number of subjects: 31
Study 36396375 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 331
Study 36396375 — intervention group
Group type: EXPERIMENTAL
Intervention: cT3 stage
Number of subjects: 331
Study 36396375 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV cancer
Number of subjects: 331
Study 36396375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram model
Number of subjects: 331
Study 36396375 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent stoma
Number of subjects: 331
Study 33714594 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D levels of 30 ng/mL and higher
Number of subjects: 144
Study 33714594 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)D as a continuous variable
Number of subjects: 144
Study 35833120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis MH‐02, 2 × 10^9 colony‐forming units per packet, once daily for 7 days
Number of subjects: 100
Study 35833120 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis subsp. lactis MH‐02
Number of subjects: 100
Study 34663673 — intervention group
Group type: EXPERIMENTAL
Intervention: Alberta Family Integrated Care (AB‐FICare)
Number of subjects: 32
Study 32649493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 7 days after 3 consecutive days of bleeding or spotting
Number of subjects: 80
Study 32649493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 80
Study 32649493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35294944 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (EA)
Number of subjects: 159
Study 35294944 — intervention group
Group type: COMPARATOR
Intervention: No analgesia
Number of subjects: 159
Study 35671033 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 502
Study 35671033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 35671033 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with comorbidity
Number of subjects: 502
Study 35671033 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin without comorbidity
Number of subjects: 502
Study 32289804 — intervention group
Group type: EXPERIMENTAL
Intervention: Single motivational lecture (2 hours)
Number of subjects: 145
Study 32289804 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 145
Study 32289804 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 145
Study 36261822 — intervention group
Group type: EXPERIMENTAL
Intervention: Free scapular flap with CAD/CAM customized osteotomy guide
Number of subjects: 22
Study 36261822 — intervention group
Group type: COMPARATOR
Intervention: Free scapular flap without CAD/CAM customized osteotomy guide
Number of subjects: 22
Study 33508239 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft-less sinus lift (group 1)
Number of subjects: 20
Study 33508239 — intervention group
Group type: COMPARATOR
Intervention: Cerabone as bone substitute (group 2)
Number of subjects: 20
Study 32429983 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention targeting both professionals and patients to improve DRS uptake, including audit/feedback, electronic prompts for professionals, HCP-endorsed reminders (face-to-face, by phone, and letter), and an information leaflet for patients.
Number of subjects: 47
Study 32429983 — intervention group
Group type: EXPERIMENTAL
Intervention: Core intervention components based on APEASE criteria.
Number of subjects: 47
Study 35442175 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming
Number of subjects: 11
Study 35442175 — intervention group
Group type: EXPERIMENTAL
Intervention: PrimingCaf
Number of subjects: 11
Study 35442175 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 11
Study 33400851 — intervention group
Group type: EXPERIMENTAL
Intervention: Downhill group (DG; n=7; downhill interval running at −10% incline)
Number of subjects: 14
Study 33400851 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill group (UG; n=7; uphill interval running at +10% incline)
Number of subjects: 14
Study 35135481 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 0
Study 35135481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34171466 — intervention group
Group type: EXPERIMENTAL
Intervention: US-ESP block
Number of subjects: 100
Study 34171466 — intervention group
Group type: COMPARATOR
Intervention: Control (opioid-based multimodal analgesia)
Number of subjects: 100
Study 32302798 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with dementia undergoing oral and maxillofacial surgery
Number of subjects: 2420
Study 32302798 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing other than dentoalveolar surgery with dementia
Number of subjects: 2420
Study 32302798 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients undergoing dentoalveolar surgery
Number of subjects: 2420
Study 32302798 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age in patients undergoing dentoalveolar surgery
Number of subjects: 2420
Study 32302798 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher anesthesiological risk in patients undergoing dentoalveolar surgery
Number of subjects: 2420
Study 35244704 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate, 1.0 mg, twice daily for 12 weeks and nicotine patch at manufacturer‐recommended doses for 10 weeks
Number of subjects: 122
Study 35244704 — intervention group
Group type: COMPARATOR
Intervention: Placebo and nicotine patch
Number of subjects: 122
Study 33979229 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SOC)
Number of subjects: 145
Study 33979229 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus topical oxygen therapy (SOC plus TOT)
Number of subjects: 145
Study 33979229 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (SOC) and Standard care plus topical oxygen therapy (SOC plus TOT)
Number of subjects: 145
Study 33879529 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcuff cuffed ETT
Number of subjects: 76
Study 33879529 — intervention group
Group type: COMPARATOR
Intervention: Portex uncuffed ETT
Number of subjects: 76
Study 32065309 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 38
Study 32065309 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 38
Study 35818036 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instruction group
Number of subjects: 90
Study 35818036 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo instruction group (immediate education)
Number of subjects: 90
Study 35818036 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video group (immediate education)
Number of subjects: 90
Study 35818036 — intervention group
Group type: EXPERIMENTAL
Intervention: Photo instruction group (advance education)
Number of subjects: 90
Study 35818036 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video group (advance education)
Number of subjects: 90
Study 35818036 — intervention group
Group type: COMPARATOR
Intervention: Verbal instruction group (immediate education)
Number of subjects: 90
Study 33077259 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 446
Study 33077259 — intervention group
Group type: COMPARATOR
Intervention: High-grade serous (HGS) OC
Number of subjects: 446
Study 33077259 — intervention group
Group type: COMPARATOR
Intervention: IA/IB/IC1 high-grade serous ovarian cancer (HGSOC)
Number of subjects: 446
Study 33077259 — intervention group
Group type: COMPARATOR
Intervention: Clear cell (CC) OC
Number of subjects: 446
Study 33283468 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine dentifrice
Number of subjects: 60
Study 33283468 — intervention group
Group type: EXPERIMENTAL
Intervention: CSPS dentifrice
Number of subjects: 60
Study 33283468 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice (control)
Number of subjects: 60
Study 32962724 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM
Number of subjects: 41
Study 32962724 — intervention group
Group type: COMPARATOR
Intervention: PED
Number of subjects: 41
Study 32962724 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 41
Study 35727655 — intervention group
Group type: EXPERIMENTAL
Intervention: Autospreader flap
Number of subjects: 48
Study 35727655 — intervention group
Group type: COMPARATOR
Intervention: Spreader graft
Number of subjects: 48
Study 35727655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 34319971 — intervention group
Group type: EXPERIMENTAL
Intervention: Early assessment and intervention by a health and social care professional team (HSCP) in the ED
Number of subjects: 353
Study 34319971 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 353